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Abstract
Background: The recent increase of breast cancer mortality has put on alert to most countries in the region.
However it has taken some time before breast cancer could be considered as a relevant problem. Only in recent
years breast cancer has been considered a priority in some Latin American countries and resources have been
mobilized to confront the problem at the institutional level. The article analyzes the efforts made in five Latin
American countries (Argentina, Brazil, Colombia, Mexico and Venezuela) in the last 15 years to design and
implement policies to address the growing incidence of breast cancer.
Methods: Data was collected between July and December 2010 from both primary and secondary sources.
Semi-structured interviews were conducted with key informants from governmental and non-governmental
organizations. Secondary data was obtained from publications in journals, government reports and official statistics
in each country. Analysis combines information from both types of sources.
Results: Countries have followed different paths and are in different stages of policy implementation. In all cases
early detection is a key strategy. Through the design of programs and guidelines, the allocation of financial resources
to treat patients, as well as a formally structured information system, Brazil and Mexico have been able to set
up comprehensive national policies. Argentina, Colombia and Venezuela have made important advancements
but not yet capable of coordinating comprehensive national policies.
Conclusion: Breast cancer is being considered a priority in all five countries but there are different stages in
the rolling out of comprehensive national policies due to differences in their capacity to allocate resources,
implement operational strategies and encourage the participation of relevant stakeholders.
Keywords: Public policy, México, Breast cancer
Background
Breast cancer mortality has been increasing significantly
in the last decade in Latin America (LA). Epidemiological
trends follow those identified in industrialized nations
20 years ago. Breast cancer is becoming an enormous
challenge in developing countries together with diabetes,
hypertension and obesity, among others [12, 19, 41].
Breast cancer mortality rate is increasing in most LA
countries [14, 24, 26, 29] unlike cervical cancer that
has been declining in recent years mainly due to the
expansion of policies that promote –among other strat-
egies- the dissemination of condoms as a barrier to the
transmission of HPV, considered the infectious agent
of cervical cancer [47, 51, 60]. However, breast cancer
has not proved to be an infectious disease, thus de-
manding different coping strategies featuring the use of
technologies and resources as well as behavioral
changes based on promoting an active participation
in screening programs along with the identification
of emergency signs in order to trigger a care-seeking
behavior [25, 61].
Breast cancer policies in the region normally share re-
sources and are implemented jointly with those regarding
cervical cancer. However the etiology of both diseases is
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completely different, moreover, it has been mentioned that
their epidemiological trends also vary [50]. Unlike cervical
cancer, breast cancer has not been specifically linked to
just one cause, there are however a whole group of poten-
tial determinants. This feature makes it impossible to es-
tablish policies based on primary preventive actions. The
most commonly used strategy is early detection which is
considered to be a secondary preventive action [45].
Early detection is relevant because the earlier a cancer
lesion is identified, the probability of survivorship in-
creases, the invasive procedures can be avoided and the
cost of treatment can be kept at a minimum [2, 7, 57].
In most industrialized countries early detection is guar-
anteed by screening female populations among age
groups of 40–50 [16]. Mammography is the technology
used to confirm initial diagnosis but the controversy
about its efficacy is still open [27]. Nevertheless, indus-
trialized countries have seen an important reduction in
their mortality rates in recent years following a broad
mammographic screening [6, 28].
Based on these facts, Latin American countries have
started to develop governmental actions towards the im-
plementation of a policy [17] to tackle the increase in
breast cancer. It is important to assess the progress of
recent developments heading towards the constitution
of goal-oriented, structured and financed policies.
Theoretical framework
According to Gilson [15] there are two main perspec-
tives to define what health policy is about. First, the
technical perspective that seeks to underpin the develop-
ment of new policy or evaluates the result of a policy
process in terms of the potential health benefits. Second,
a more political and organizational approach that in-
tends to understand the process in itself by identifying
interested actors (individual, group or institutional) and
their capacity to influence the policy process.
Those who adhere to the first perspective argue that it
is possible to identify stages in the policy process while
those who have a political perspective of the policy
process do not assume that these stages are sequential
or those they always occur in every decision-making
process. Furthermore the second group tends to focus
on the dynamics of human interaction, its modalities,
and the role of hidden agendas and the capacity of
individuals or groups to bias the process towards their
particular interests.
Corkery, et al, [10] argue that the creation of a policy
can be identified when incumbent actors, are capable of
stating specific objectives that respond to a certain
health problem. Incorporating the issue into the political
agenda is the first step in turning it into a governmental
priority. These objectives together with sound justifica-
tions and a normative frame have been incorporated into
documents to be approved by legislative branches of
government [1]. Most of these documents have a com-
pulsory nature regulating the participation of interested
parties. Normally policies derive into programs, guide-
lines and norms that specify the legal, administrative
and technical nature of the activities to be carried out.
Once policies are legally approved, they are frequently
granted public resources to coordinate the implementa-
tion of concrete actions to accomplish the defined objec-
tives. However, as initially mentioned, in most policy
processes, these stages do not take place sequentially but
they generally follow iterative patterns until final defini-
tions are reached.
The analysis of breast cancer policies can be carried
out based on the previous considerations but as in the
majority of available policy analysis –including those in-
terested in health issues- specificities should be consid-
ered to identify those key elements that characterize
their essential nature [17]. In our case, a major consider-
ation is that in Latin America and the Caribbean most
breast cancer policies are actually being developed,
clearly showing gaps in their technical and managerial
definitions. A second consideration is that policies in the
region are articulated based on the experience of
European countries, USA and Canada but under differ-
ent social, cultural and health conditions [58]. Third,
they are framed in health systems that are being re-
formed aiming to develop stronger financial schemes,
achieve universal coverage, increase the availability of re-
sources (including information) and open up the system
to the participation of more social actors [61, 62].
Existing breast cancer policies consider early detection
as a key activity. However there are different ways to
carry out this activity, which greatly depend on the
structural characteristics of health care systems [3]. For
example, health care systems have a better possibility of
organizing successful screening programs when broad
segments of the population have access to them.
Governmental entities are responsible for undertaking
the stewardship role in the development and implemen-
tation of policies [5, 28]. Also major challenges emerge
for the stewardship role when health systems are seg-
mented or fragmented [39, 40]. Decentralization also
implies a major challenge as local entities can identify
their own priorities and implement their own policies,
particularly when taxes are collected at that level [10]. In
most cases, reference systems find enormous difficulties
to operate due to the lack of organization, coordination
and poor management [40].
In all stages of public policy, a diversity of actors are
commonly involved. Policy is of course not only preroga-
tive of public institutions but more recently following the
increasing democratization in developing countries, civil
society has emerged as a powerful actor [46] in its own
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right. In female cancers an important source of interest is
the universal movement towards gender equity in health
[53]. Civil society organizations (CSOs) currently partici-
pate in all stages of breast cancer policy. More recently
CSOs and governmental entities seem to have found posi-
tive ways of interacting, which can promote that policies
benefit targeted populations and not only interest groups
which is always an inherent risk [4].
Most specialists convey that the generation of data and
the analysis derived from it, is key in the policy cycle [22].
Data can be used to identify priorities, to draw up plans
and programs and implement new operational mecha-
nisms. Data can also be used to evaluate policy. Evaluating
of policy is a key stage in identifying the achievement of
defined goals. Moreover, data obtained from evaluations
can be used to identify deviations in the policy process
[52]. Data dissemination to interested parties is also a key
democratic tool capable of informing society about the
use of public resources and its consequences [43].
The following sections rely on a study carried out at
the end of 2010 in five LA countries, Argentina, Brazil,
Colombia, Mexico and Venezuela in order to assess the
definition and implementation of breast cancer policy,
the participation of CSOs in these endeavors and the
capacity to set up routine data collection to evaluate and
monitor the development of policy.
Methods
The scarcity of information regarding breast cancer pol-
icies in LA [2, 17, 31, 44] motivated the development of
a research project by a team of researchers from the
National Institute of Public Health (NIPH) of Mexico
between July and November of 2010 with support from
the American Cancer Society.
The original study was based on a mixed-methods
design. However, this article focuses only on the qualitative
component that contains the core data used for the analysis
of policies. Sample selection was intentional and carried
out in two stages. In the first stage, countries were selected
using the following criteria: a) structural diversity of health
systems b) prevalence, incidence and mortality rates, c)
variety of financing mechanisms, and d) participation of
various stakeholders in the definition of breast cancer
policy. In the second stage, key informants were selected
from governmental and non-governmental organizations
using the snow-ball technique [38, 54] from each of the
selected countries (Table 1).
Information was obtained by means of primary and
secondary sources. In the first case, semi-structured in-
terviews were applied to representatives from central
and local government, CSOs’ personnel, professional
associations’ representatives, and academics with ex-
perience in the field of breast cancer care. The final
sample of informants was 65 in all five countries con-
sidered (Table 2).
Interviews were carried out in Spanish and Portuguese.
A piloted semi-structured questionnaire was applied
which facilitated the systematic exploration of topics. All
informants provided a verbal informed consent before
the interview. The main explored topics were the exist-
ence of national/local policies for breast cancer care, the
implementation of policies through specific activities,
the participant actors, resources available and finally, the
attainment of objectives and goals.
Table 1 Health Systems characteristics of five Latin American countries
Country Total Population
(thousands)








Public Social security Private Public Private
Argentina 41,119 30.2 % 60.8 % 9 % Fragmented 6.2 3.2 Not available
Brasil 198,361 75 % 0 % 25 % Unified 3.1 4.1 15.1





Subsidized regime: 51.4 %
Special regimes: 4.6 %













Not available 2.4 Not available
Source: Panamerican Health Organization (PAHO). Health situation in the Americas. Basic Indicators 2012. Available
on: http://ais.paho.org/chi/brochures/2012/BI_2012_ENG.pdf
aPan American Health Organization. Health in the Americas: 2012 Edition. Regional Outlook and Country Profiles. Washington, DC: PAHO, 2012
bGutiérrez JP, Hernández-Ávila M. Health protection coverage in Mexico and profile of unprotected population, 2000–2012. Salud Publica Mex 2013:55
suppl 2:S83–S90
cBonvecchio A, Becerril-Montekio V, Carriedo-Lutzenkirchen A, Landaeta-Jiménez M. The health system of Venezuela. Salud Publica Mex 2011;53
suppl 2:S275–S286
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Secondary sources gathered published and non-
published official documents containing availability of
physical, technological, human and financial resources to
support the care of breast cancer as well as laws, guide-
lines, plans, programs, evaluation reports, clinical prac-
tice guidelines and articles addressing these topics
(Table 3).
The processing of data from primary sources started
with the transcription of audio recordings into Word
format files. Data analysis (from primary and secondary
sources) was guided through the design of codes orga-
nized by previously defined topics and sub-topics by the
research team. A flexible approach was followed through-
out the process in the integration and systematization of
new information in order to identify emerging issues.
The project was approved by the Research and Ethics
Committees of the National Institute of Public Health of
Mexico # CI: 944, 944 September 27/2010.
Results
Summarized in Table 4, results are presented in four
sections as follows: a) definition of specific policy to con-
front breast cancer, b) early detection strategy, c) civil
society participation, and d) information systems.
a) Definition of policy to confront breast cancer
The following elements were found among the group of
countries to inform and characterize the development of
breast cancer policy: 1) breast cancer as priority in the
public health agenda, 2) allocation of specific funds to
cover for breast cancer care, 3) the capacity of the
central government to carry out and monitor the ap-
plication of operational guidelines.
Even though breast cancer is identified as an import-
ant public health problem in all countries, only the
Brazilian and Mexican health authorities have recog-
nized it as a health priority. In these countries it has
been incorporated as such in the public policy agenda
([32, 49]). In Argentina in spite of the fact that the
rate of breast cancer mortality (21.8 per 100,000
women) is second in LA only behind Uruguay, vari-
ous informants expressed that breast cancer is far
away from being considered a public health priority.
One of them pointed out:
“Up to now, the government has said very little (about
breast cancer policy).Plans were initiated and quickly
disappeared. The current expectation is that the (new)
National Cancer Institute could provide an assessment
to understand the situation and see what we can do.
(Argentina 4)
Regarding financing, all breast cancer cases attended
by the public system in Mexico and Brazil have guaran-
teed funds to cover all stages of the disease. In Venezuela,
specific financing only exists for chemotherapy, which is
managed by the Venezuelan Institute of Social Security.
Argentina presents an opposite scenario considering that
major problems were identified because breast cancer
financing depends on the type of service package that dif-
ferent groups of populations are entitled to receive, gener-
ating major inequities in the possibility of these groups to
have access to cancer care. In Colombia, before 2011, the
scenario was similar to Argentina given the important
differences between services packages provided to popula-
tions that were contributing to the social security fund
and those who were fully subsidized by the state [55].
However, this scenario may have changed already –at least
Table 2 Informants by country
Type of informant Mexico Colombia Venezuela Brazil Argentina Total
Public sector 7 5 3 3 5 23
Civil society organization 3 5 8 3 3 22
Professional society 0a 1 3 3 1 8
Other stakeholder 4 2 4 1 1 12
Total 14 13 18 10 10 65
Source: own elaboration with data obtained from secondary sources
aIn Mexico, it was not possible to interview an authorized representative of professional associations. However, a number of public sector respondents belonged
to professional groups. An extended interview was carried out in these cases
Table 3 Secondary information by country
Data source Mexico Colombia Venezuela Brazil Argentina
Women’s health
program




Yes Yes Yes Yes Yes
Breast cancer policies Yes Yes No Yes Yes
Breast cancer care/
control programs
Yes No Yes Yes Yes
Breast cancer
treatment consensus








Yes No No Yes No
Source: Own elaboration with information from secondary sources
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Table 4 Summary of basic epidemiological data and policy results by country




Specific breast cancer policy Early detection strategy Civil society and civic participation Information system
Mexico Incidence: 27.2 Yes. Supported by a program
with defined objectives and goals.
Organized opportunistic mammography screening
program for women 40–69 years old.
High level of participation in the areas
of education, research, service provision
and lobbying but atomized.
Yes. SICAM PRO-MAMA is
a routine data collection
system.Mortality: 10.1
Colombia Incidence:31.2 No. Recently approved a cancer
care law. National Cancer Institute
is involved in policy.
Opportunistic mammography screening for both
contributory and subsidized regimens. Not fully
organized. Annual mammography starting at
49 years of age, except for symptomatic cases
and the related risks.
High level of participation in the areas
of education, research, service provision




Venezuela Incidence: 42.5 Not. The Ministry of Health has an
under-funded sub-program for
breast cancer control.
Sub-program with indications for opportunistic
mammography screening carried out differently
in each state. Starting age of mammography
35 years and for women with known risk
factors at low age.
Low level of participation in program
and policy definition. Active participation
in educational activities and support for
women with breast cancer.
Yes. Data collection is
problematic and not
all stakeholders are
aware of its existence.
Mortality: 13.7
Brazil Incidence:42.3 Yes. Supported by a program
with defined objectives and goals.
Organized opportunistic mammography screening
program for women 35 years and older and for
women with known risk factors less than 35 years old.
High level of organized participation.
Assigned seats in state and municipal
health councils.
Yes. SISMAMA is a
routine information
collection system.Mortality: 12.3
Argentina Incidence: 74.0 Not at the national level. Some
provinces have well developed
policies.
No national screening program due to decentralized
health system structure. In generally annual
mammography starting from 49 years of age, except
for symptomatic cases and the
Low level of participation in program




















referring to treatment- following two legislative important
changes: 1) the leveling of services packages between
both types of populations [9], and 2) the definition of
specific financing for breast cancer care within the social
security fund [36].
Although all countries have programs, laws and/or
clinical guidelines for breast cancer care, its implementa-
tion and operation is very lopsided both between and
within each of the countries. In this sense all countries,
with the exception of Venezuela, have set up National
Cancer Institutes to carry out stewardship functions.
However, the specific roles of Institutes differ according
to the country. In Argentina, the new Cancer Institute
created by presidential decree, is responsible for design-
ing and guiding the implementation of a policy to com-
bat different types of cancer, including breast cancer.
The institute has been engaged, since its foundation, in
negotiations with decentralized provinces for the defin-
ition of programs and specific guidelines for cancer care,
a major objective in breast cancer is to set up a program
for early detection. Brazil’s National Cancer Institute
(INCA) has the dual function of guiding policy and
providing hospital services to the population in the
State of Rio de Janeiro. Its main specific function is to
define national guidelines and try to negotiate its appli-
cation in the more than 5,000 Brazilian municipalities.
INCA also carries out research at different levels in
order to produce evidence to back up its decisions.
National Cancer Institutes in Mexico and Colombia
share a specific focus on service provision. They were
originally designed to provide hospital cancer care to
the population. The Mexican institute also carries out
clinical and epidemiological research. Both of them
participate in the definition and monitoring of policy.
Although neither of them is responsible for imple-
menting policy, they do serve as advisory bodies to ex-
ecutive units.
b) Early detection strategy
Early detection of breast cancer is a key activity in each
country. However variations in its implementation can
be identified.
In general, early detection policy calls for an annual or
biannual mammography starting at age 50. However, in
seeking to meet the specific needs of their at-risk popu-
lations, each country has adjusted the age group in
which a mammography is to be initiated. Debate persists
among government and non-government stakeholders
on the appropriate age for initiating routine mammog-
raphy [8, 11]. The increasing amount of women dying at
young ages in LA has raised the possibility of lowering
the age for a routine mammography initiation, as it was
referred by a middle-level decision maker from the
Mexican public health system:
“In the year 2009, the updating process of the
Breast Cancer Official Norm started. This process
engaged into the discussion of lowering the age of
the start of screening mammography down to
40 years, based on the existence of new
epidemiological evidence that stated that breast
cancer in Mexico was appearing at younger ages. In
these discussion the main participants were the
government, the academia and civil society
organizations”(Mexico 5)
In Brazil, a law was passed in 2009 to guarantee that
every asymptomatic woman aged 35 or older would re-
ceive a mammography provided by public institutions
on yearly basis and those who are under 35 if they
present suspicious signs or have direct family history of
breast cancer. In Venezuela, access to biannual mam-
mography starts at age 35. In Mexico, the age for routine
annual mammogram initiation (regardless of risk factor
profile) was programmatically reduced after a two-year
process of technical standard review.1 Colombia and
Argentina preserve their initial definition of yearly mam-
mography starting at 50, except for symptomatic and
risk-related cases.
Nevertheless, early detection programs in all countries
have major challenges to overcome. All of them follow
an “opportunist” strategy where the possibility of de-
tecting a woman with breast cancer depends on the
probability that the person reaches the services which
is unlike most European strategies that target all
population at risk. Scarcity of resources and little
awareness in the population have combined to pro-
duce poor results in early detection programs. In all
countries the percentage of women who are detected
at early stages is quite low [37, 48, 59]. In Brazil it
has been estimated at 10 % [18]. Furthermore, inequi-
ties exist. In Argentina and Venezuela there is no na-
tional strategy of early detection and the possibility of
having such a strategy depends on the province or
state defining it as a priority and consequently allo-
cating resources. In Mexico and Colombia women
who are covered by the employees’ contributive sub-
system have a higher chance of early detection
compared to those financed and assisted by the public
system. An informant from the Ministry of Health of
Colombia stated the following:
“There is an enormous gap in the timely detection of
breast cancer due to the fragmentation of the health
care system in two insurance modalities: the
contributory and the subsidized. The first one has
defined that it should reach 20 % of mammographic
screening of its target population while the second has
not established any goal at all” (Colombia 5)
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c) Civil society and citizen’s participation
Civil society participation in Argentina and Venezuela is
at the more spontaneous end of the spectrum. In
Argentina various organizations have participated in
promoting health activities for decades, though relation-
ships with government institutions tend to be weak.
One exception is the Argentine League to Fight Cancer,
which plays a distinct advisory role to health authorities
regarding clinical care issues. In Venezuela the gap be-
tween health authorities and CSOs is so wide that the
latter practically do not participate in any decisions related
to breast cancer policy. In contrast, active dialogue to put
pressure on government institutions was observed in
Brazil, where CSOs have been incorporated into the struc-
ture of local government and state councils, making their
voices significantly represented in many of the decisions
made at different levels. One case to highlight is the
Brazilian Federation of Philanthropic Institutions in
Support to the Health of the Breast (FEMAMA) who has
actively participated over a long period of time in the pass-
ing of the 2009 mammography norm. About this issue,
one of the informants pointed out:
“In 2002 conversations started to define a breast
cancer policy. Once the analysis was completed in
2003, the ministry of health called upon the civil
society and decision makers to debate about cancer
policy” (Brazil 3)
Key organizations have shown leverage in Mexico and
Colombia and have successfully put pressure on health
authorities when making decisions at the programmatic
and policy level. CSOs have been particularly active
in updating technical standards for breast cancer care
in Mexico.
In all five countries, there are an increasing number of
international stakeholders participating in various fronts.
The pharmaceutical global corporate industry is partici-
pating using local CSOs as recipients of their support.
For example, CIMA*B in Mexico and SenoSalud in
Venezuela receive funds from companies to carry out
their activities. Other non-pharmaceutical companies
such as Avon, Caterpillar, General Motors, etc., also pro-
vide support to NGOs in order to carry out their advo-
cacy roles. All corporations supporting CSOs obtain at
least non-tangible benefits such as prestige and positive
social image. Some CSOs are particularly successful in
raising funds from various corporative sources in order
to expand their capacity and influence. Not only are
private for-profit businesses involved. The American
Cancer Society (ACS), one of the most influential global
cancer CSO supports local CSOs to carry out their advo-
cacy roles through the provision of technical advice based
on research evidence that ACS contracts. ACS has also
supported the development of a regional organization
called the Latin American Union for Breast Cancer
(ULACCAM in Spanish) aiming at disseminating infor-
mation throughout the region about participation strat-
egies in the breast cancer arena. Another area of
participation is through the implementation of clinical
guidelines that have been drawn up to establish the basic
conditions in providing breast cancer care. The Breast
Global Health Initiative (BGHI) has developed a set of
guidelines adapted to the needs of developing countries.
BGHI has been trying to introduce its guidelines in LA
with relative success. It is clear that international stake-
holders have an important presence in the breast cancer
field in all the studied countries.
d) Information systems
Epidemiological information systems in Brazil and Mexico
routinely produce information which allows prevalence,
incidence and mortality to be estimated throughout the
entire country. In contrast, Colombia, Argentina and
Venezuela do not have national information systems that
routinely collect information and are unable to monitor
policy or program outcomes. However, alternative sources
of information provide certain useful data for monitoring
activities. In the words of a decision maker from the
Venezuelan public health system:
“Cancer registries have faced serious difficulties to
have available enough human, material and financial
resources to guarantee their continuous operation.
These difficulties have affected the continuity of
recordings, affecting quality and coverage targets”
(Venezuela 3)
A variety of structures and processes in the collection
and use of information were observed. Brazil and
Mexico have advanced the most in the implementation
of specific information systems for different types of
cancer. In Mexico, an information system for monitoring
breast cancer care procedures has only recently been
created, nevertheless, this step is crucial for policy
monitoring at a time when breast cancer programs are
in an expansion phase. In Brazil, INCA operates an
information system that collects population based indi-
cators as well as service provision indicators from all
states and municipalities.
The way health care is financed and organized in
Colombia substantially affects the collection and use of
its information system. Organizations with health insur-
ance functions called Management Companies Benefit
Plans allocate funding to pay for health care and there-
fore have incentives to collect information on system
users. While no mechanism currently exists to use infor-
mation from these Entities for national policy monitoring,
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the National Cancer Institute is making a major effort to
build an information system that meets these require-
ments. In Argentina the newly created Cancer Institute
may help to overcome its information gaps in the coming
years, as it is being depicted by the following testimony:
“What the Institute of Cancer should do is to put
together all registries (..) available throughout the
country. We have registries in various provinces
even in (small) localities such as Venados
Blancos.”(Argentina 4).
Table 4 summarizes a set of qualitative indicators used
in the description of previous sections. Key information
is included in each column to allow the situation of each
of the five countries to be compared.
Discussion
Although data collection showed that there is no specific
sequence in the development of breast cancer policy
stages in any of the countries, it was possible to identify
four features that are common and relevant to provide a
clear response to the breast cancer epidemics (definition
of a specific policy, existence of an early detection strategy,
civil society participation and development of information
systems). However, there are important differences in the
way they have developed in each country due to social
and institutional traditions as well as the capacity of each
country to allocate financial resources for their implemen-
tation. Although information obtained by the research
was originally collected in 2010, the picture that is por-
trayed upon the description of the cases has not really
changed in the last five years, except for Brazil. In this
country a norm was recently approved [23] stating that no
more than 60 days should pass between the diagnosis and
the start of the treatment for all cancer patients. Further-
more, the public system is providing access to oral chemo-
therapy which allows patients in good physical conditions
to receive treatment at home and, finally, Trastuzumab is
now being provided to all breast cancer patients and is
paid by the public system. However, over this period of
time, the private sector dynamics in all countries including
CSOs participation has to be highlighted allowing these
organizations to increase their influence in designing and
implementing these policies.
All five countries have made significant progress in
ratifying national programs to combat breast cancer.
The first feature has been to understand the health
threat of breast cancer and a subsequent reaction from
health authorities and interested stakeholders. The sec-
ond important feature has been the definition of actions,
plans and programs; and the third, implementation,
which shows clear differences in progress by country
[13, 30, 56].
Brazil and Mexico have made the greatest progress in
both designing and operationalizing breast cancer policies.
Both countries have official government documents that
define the problem and describe actions to be carried out
that are linked to specific goals [33, 49]. A sustainable,
specific source of financing seems to be guaranteed in
both countries as well. However, weak spots persist in
day-to-day operations, mainly due to low coordination
capacity. Defining breast cancer as a health priority in all
Brazilian decentralized municipalities represents a major
challenge, particularly when the prevalence in northern
municipalities is quite low compared with that of the
southern region, due mostly to socioeconomic and genetic
factors [34]. Likewise, breast cancer mortality rates present
differential regional patterns in Mexico (mortality is
higher in the north than in the south), however the federal
level of government appears to be more capable of stand-
ardizing its policy actions because of its centralized finan-
cing mechanism. Mexico’s main problem is a deficit of
material and human resources [37].
In addition to regional differences in breast cancer
magnitude, the dual health system in Colombia contrib-
utes to differentiate the service provision between the
contributory and subsidized populations [55]. Although
service packages have been recently equalized, it will
take some time before historical differences in access to
cancer care disappear both in ambulatory and hospital
care. Argentina finds itself in a crucial phase in develop-
ing a breast cancer policy following the creation of its
new National Cancer Institute, whose mission is to con-
struct a harmonized health care policy for different types
of cancer featuring breast cancer as one of its top prior-
ities. While important progress has been made in the
design of a policy, all provinces must be convinced to
make a concerted effort. Finally, in Venezuela the most
important obstacles in the consolidation of a coherent
and functional breast cancer policy are the lack of co-
ordination among different sectors and the persistence
of inequities between rich and poor states.
Good policy harmonization always depends on the
implementation of high-quality information. Despite
important advances made in this area, it is imperative
that countries create and/or strengthen their monitoring
and evaluation systems. Mutual learning among LA
countries on indicator design and technological imple-
mentation is a promising strategy that could drive progress
in this area. Several voices have called about the need of
better cancer registries to produce key data to feed clinical
and policy process [21, 29, 42].
Finally, civil society plays a fundamental role in na-
tional efforts to combat breast cancer. CSOs must main-
tain their critical position but at the same time, be
proactive regarding government-initiated proposals aim-
ing at harmonizing the role of participating actors in the
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attainment of common goals. Breast cancer CSOs -many
of them supported by global stakeholders- are gaining
enormous power making them a formidable political
driving force that could be used in favor of achieving
public breast cancer goals.
Conclusions
Breast cancer care is raising awareness among LA health
authorities. This awareness is a result of both the in-
crease in the death toll in women in the last ten years as
well as the role of advocacy groups calling for a more
decisive response from governments. The countries in-
cluded in the study have already started actions to tackle
breast cancer but not all cases have developed a structured
policy. Actions differ according to the level of priority given
in every country, the financial resources involved in it, the
existence of a coordination entity at national level, the cap-
acity to produce statistical data to guide decisions and the
role of non-governmental actors (including civil society,
professional groups, media and others). It is not possible to
say at this point how successful analyzed countries will be
in fully implementing breast cancer policies and reducing
mortality in the long run but steps to accomplish that ob-
jective have been clearly identified in all of them.
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